Smith & Nephew
Website:
Smith & Nephew
Index:
FTSE 100
EPIC: SN.
Supersector:
Health Care
Sector:
Health Care Equipment and Services
Subsector:
Medical Equipment
Market Cap:
£9.71B
Payout Frequency: Semi-Annual
Smith & Nephew Dividend Analysis and Summary
Key Dividend Details
- Final dividend declared: 24.1¢ per share (48.2¢ per ADS), subject to shareholder approval.
- Total FY2025 dividend: 39.1¢ per share (78.2¢ per ADS), up +4.3% year-on-year (2024: 37.5¢).
- Payout ratio: 38% (aligned with the stated 35–40% framework).
- Ex-dividend date: 26/03/2026.
- Record date: 27/03/2026; Payment date: 27/05/2026.
- DRIP/currency election deadline: 05/05/2026.
- Currency: Dividends declared in US dollars; sterling amount to be set after the record date.
Sustainability and Growth Outlook
- Coverage: FY2025 DPS (39.1¢) is covered ~2.6x by adjusted EPS (EPSA 102.0¢) and ~1.8x by IFRS EPS (72.1¢) — solid earnings cover.
- Cash support: Free cash flow of $840m in 2025 versus dividends paid of ~$330m (~2.5x cash cover). 2026 guidance for FCF is ~$800m, still ample for the dividend even with modest growth.
- Profitability trend: Trading profit rose +15.5% to $1,211m; margin expanded to 19.7% (+160bps). 2026 trading profit expected ~$1.3bn (including small dilution from the Integrity Orthopaedics acquisition) — supportive for ongoing distributions.
- Balance sheet: Adjusted net debt/EBITDA at 1.7x, with strong liquidity and completed $500m buyback in H2 2025 — indicates capacity to maintain policy-consistent payouts.
- Dividend trajectory: With a stated payout framework of 35–40% and targets for higher growth, margins, and >$1bn FCF by 2028, the progressive, low-to-mid single digit dividend growth profile looks well supported.
Structural/Policy Factors That Could Affect Future Dividends
- Capital allocation policy: Reaffirmed payout ratio (35–40%) and disciplined reinvestment; buybacks are opportunistic (not a fixed commitment).
- Acquisition of Integrity Orthopaedics (Jan 2026): Initial cash outlay $225m plus up to $225m earn-outs; expected to be marginally dilutive to 2026 trading profit, neutral in 2027, accretive in 2028. Near-term EPS effect modest; cash generation guidance remains strong.
- Portfolio rationalisation: Ongoing simplification (non-cash inventory provision of $159m in 2025) should improve capital efficiency and margins over time — supportive for dividend capacity longer term.
- Strategy shift to RISE (2028 targets): Aims for 6–7% organic revenue CAGR, 9–10% trading profit CAGR, FCF >$1bn — if delivered, enhances dividend headroom.
Risks and Flags to Dividend Stability
- Operational headwinds in 2026: Tariffs (~$60m impact vs $17m in 2025), US wound reimbursement changes ($20–40m), and China VBP for ENT and arthroscopic technologies may pressure margins in-year.
- FX risk: Dividends are in USD; sterling receipts will vary with USD/GBP at conversion.
- Regulatory/reimbursement: Skin substitutes weakness ahead of US reimbursement changes could weigh on Advanced Wound performance near term.
- M&A execution: Earn-out obligations and integration risk (Integrity Orthopaedics) need monitoring, though leverage remains moderate and FCF guidance intact.
Read more
Smith & Nephew Annual Dividend Yield - 2.45%
Dividends Used in Calculation:
| Ex-Dividend Date |
Payment Date |
Type |
Amount |
Currency |
| 27/03/2025 |
28/05/2025 |
Final |
23.10¢ |
USX |
| 02/10/2025 |
07/11/2025 |
Interim |
15.00¢ |
USX |
Total (Annual Dividends Per Share):
28.05p
(Using exchange rate on 30/04/2026
$ = £0.73627)
Dividend Yield =
Annual Dividends Per Share (28.05p)
÷ Share Price (1147p)
= 2.45%
Smith & Nephew Dividend History
| Ex Dividend Date |
Payment Date |
Type |
Amount |
Currency |
| 26/03/2026 |
27/05/2026 |
Final |
24.10¢ |
USX |
| 02/10/2025 |
07/11/2025 |
Interim |
15.00¢ |
USX |
| 27/03/2025 |
28/05/2025 |
Final |
23.10¢ |
USX |
| 03/10/2024 |
08/11/2024 |
Interim |
14.40¢ |
USX |
| 28/03/2024 |
22/05/2024 |
Final |
23.10¢ |
USX |
| 05/10/2023 |
01/11/2023 |
Interim |
14.40¢ |
USX |
| 30/03/2023 |
17/05/2023 |
Final |
23.10¢ |
USX |
| 29/09/2022 |
26/10/2022 |
Interim |
14.40¢ |
USX |
| 31/03/2022 |
11/05/2022 |
Final |
23.10¢ |
USX |
| 30/09/2021 |
27/10/2021 |
Interim |
14.40¢ |
USX |
| 01/04/2021 |
12/05/2021 |
Final |
23.10¢ |
USX |
| 01/10/2020 |
28/10/2020 |
Interim |
14.40¢ |
USX |
| 02/04/2020 |
06/05/2020 |
Final |
23.10¢ |
USX |
| 03/10/2019 |
30/10/2019 |
Interim |
14.40¢ |
USX |
| 04/04/2019 |
08/05/2019 |
Final |
22.00¢ |
USX |
| 04/10/2018 |
31/10/2018 |
Interim |
14.00¢ |
USX |
| 05/04/2018 |
09/05/2018 |
Final |
22.70¢ |
USX |
| 05/10/2017 |
01/11/2017 |
Interim |
12.30¢ |
USX |
| 30/03/2017 |
10/05/2017 |
Final |
18.50¢ |
USX |
| 06/10/2016 |
25/10/2016 |
Interim |
12.30¢ |
USX |
| 21/04/2016 |
11/05/2016 |
Final |
19.00¢ |
USX |
| 08/10/2015 |
27/10/2015 |
Interim |
11.80¢ |
USX |
| 16/04/2015 |
06/05/2015 |
Final |
18.60¢ |
USX |
| 23/10/2014 |
11/11/2014 |
Interim |
11.00¢ |
USX |
| 16/04/2014 |
07/05/2014 |
Final |
17.00¢ |
USX |
| 09/10/2013 |
29/10/2013 |
Interim |
10.40¢ |
USX |
| 17/04/2013 |
08/05/2013 |
Final |
16.20¢ |
USX |
| 10/10/2012 |
30/10/2012 |
Interim |
9.90¢ |
USX |
| 18/04/2012 |
09/05/2012 |
Final |
10.80¢ |
USX |
| 12/10/2011 |
01/11/2011 |
Interim |
6.60¢ |
USX |
| 29/04/2011 |
19/05/2011 |
Final |
9.82¢ |
USX |
| 13/10/2010 |
02/11/2010 |
Interim |
6.00¢ |
USX |
| 21/04/2010 |
12/05/2010 |
2nd Interim |
8.93¢ |
USX |
| 14/10/2009 |
03/11/2009 |
Interim |
5.46¢ |
USX |
| 15/04/2009 |
08/05/2009 |
2nd Interim |
8.12¢ |
USX |
| 15/10/2008 |
07/11/2008 |
Interim |
4.96¢ |
USX |
| 16/04/2008 |
09/05/2008 |
2nd Interim |
7.38¢ |
USX |
| 17/10/2007 |
09/11/2007 |
Interim |
4.51¢ |
USX |
| 18/04/2007 |
11/05/2007 |
2nd Interim |
6.71¢ |
USX |
| 18/10/2006 |
10/11/2006 |
Interim |
4.10¢ |
USX |
| 19/04/2006 |
12/05/2006 |
2nd Interim |
6.10¢ |
USX |
| 19/10/2005 |
11/11/2005 |
Interim |
3.66¢ |
USX |
| 20/04/2005 |
13/05/2005 |
Final |
5.879¢ |
USX |
| 20/10/2004 |
12/11/2004 |
Interim |
3.524¢ |
USX |
| 21/04/2004 |
14/05/2004 |
Final |
5.010¢ |
USX |
| 13/08/2003 |
12/09/2003 |
Interim |
2.969¢ |
USX |
| 20/04/2003 |
16/05/2003 |
Final |
4.87¢ |
USX |
| 16/10/2002 |
15/11/2002 |
Interim |
2.84¢ |
USX |
| 17/04/2002 |
17/05/2002 |
Final |
4.150¢ |
USX |
| 07/11/2001 |
05/12/2001 |
Interim |
2.478¢ |
USX |
| 18/04/2001 |
18/05/2001 |
Final |
4.013¢ |
USX |
| 08/11/2000 |
06/12/2000 |
Interim |
2.443¢ |
USX |
| Year |
Interim |
Final |
Currency |
Total |
Change |
| 2024 |
14.400 |
23.100 |
USX |
37.500 |
0.000 |
| 2023 |
14.400 |
23.100 |
USX |
37.500 |
0.000 |
| 2022 |
14.400 |
23.100 |
USX |
37.500 |
-38.110 |
| 2021 |
14.400 |
46.200 |
USX |
60.600 |
61.600 |
| 2020 |
14.400 |
23.100 |
USX |
37.500 |
3.020 |
| 2019 |
14.400 |
22.000 |
USX |
36.400 |
-0.810 |
| 2018 |
14.000 |
22.700 |
USX |
36.700 |
198.370 |
| 2017 |
12.300 |
|
USX |
12.300 |
-75.300 |
| 2016 |
12.300 |
37.500 |
USX |
49.800 |
63.810 |
| 2015 |
11.800 |
18.600 |
USX |
30.400 |
8.570 |
| 2014 |
11.000 |
17.000 |
USX |
28.000 |
5.260 |
| 2013 |
10.400 |
16.200 |
USX |
26.600 |
28.500 |
| 2012 |
9.900 |
10.800 |
USX |
20.700 |
26.060 |
| 2011 |
6.600 |
9.820 |
USX |
16.420 |
9.970 |
| 2010 |
6.000 |
|
USX |
14.930 |
9.940 |
| 2009 |
5.460 |
|
USX |
13.580 |
10.040 |
| 2008 |
4.960 |
|
USX |
12.340 |
9.980 |
| 2007 |
4.510 |
|
USX |
11.220 |
10.000 |
| 2006 |
4.100 |
|
USX |
10.200 |
6.920 |
| 2005 |
3.660 |
5.879 |
USX |
9.539 |
11.770 |
| 2004 |
3.524 |
5.010 |
USX |
8.534 |
8.860 |
| 2003 |
2.969 |
4.870 |
USX |
7.839 |
12.140 |
| 2002 |
2.840 |
4.150 |
USX |
6.990 |
7.680 |
| 2001 |
2.478 |
4.013 |
USX |
6.491 |
165.690 |
| 2000 |
2.443 |
|
USX |
2.443 |
|
Smith & Nephew Dividend Calculator
Smith & Nephew Dividend Growth
| Dividend Growth (1Y) |
-2.87%
|
| Dividend CAGR (5Y) |
0.75%
|
| Years of Growth |
–
|
| Payout Ratio |
52.8%
|
| Buyback Yield |
0.34%
|
| Shareholder Yield |
2.79%
|
| P/E Ratio (TTM) | 22.57 |
| Forward P/E | 14.33 |
| P/FCF | 16.12 |
| Earnings Yield | 4.55% |
| FCF Yield | 6.2% |
| ROE | 11.84% |
| ROCE | 9.9% |
| Profit Margin | 10.14% |
| Operating Margin | 14.23% |
| Gross Margin | 68.25% |